Anti-CD146 Antibody (AA98)

Anti-CD146 Antibody (AA98) 是一种靶向 CD146 的抗体和血管生成抑制剂,可阻断 CD146 的二聚化及其下游 PI3K/AKT、p38 MAPK、NF-κB 信号通路,抑制 MMP9、ICAM1 的表达、上皮间质转化 (EMT) 以及内皮细胞的增殖、迁移和成管作用,增强辐射诱导的癌细胞凋亡 (apoptosis) 及存活抑制,降低肿瘤微血管密度,并抑制肿瘤生长、侵袭和血管生成拟态,可用于宫颈癌、肝癌、恶性乳腺叶状肿瘤、葡萄膜黑色素瘤、平滑肌肉瘤、胰腺癌及其他肿瘤、血管生成的相关研究。
Anti-CD146 Antibody (AA98)
产品编号: MS-O94874
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价

产品描述

Anti-CD146 Antibody (AA98) 是一种靶向 CD146 的抗体和血管生成抑制剂,可阻断 CD146 的二聚化及其下游 PI3K/AKT、p38 MAPK、NF-κB 信号通路,抑制 MMP9、ICAM1 的表达、上皮间质转化 (EMT) 以及内皮细胞的增殖、迁移和成管作用,增强辐射诱导的癌细胞凋亡 (apoptosis) 及存活抑制,降低肿瘤微血管密度,并抑制肿瘤生长、侵袭和血管生成拟态,可用于宫颈癌、肝癌、恶性乳腺叶状肿瘤、葡萄膜黑色素瘤、平滑肌肉瘤、胰腺癌及其他肿瘤、血管生成的相关研究。

生物实验数据

生物活性 Anti-CD146 Antibody (AA98) is an antibody targeting CD146 and an angiogenesis inhibitor that blocks CD146 dimerization and its downstream PI3K/AKT, p38 MAPK, and NF-κB signaling pathways, inhibits the expression of MMP9 and ICAM1, epithelial-mesenchymal transition (EMT), and the proliferation, migration, and tube formation of endothelial cells, enhances radiation-induced apoptosis and survival inhibition of cancer cells, reduces tumor microvessel density, and suppresses tumor growth, invasion, and vasculogenic mimicry, and can be used for research related to cervical cancer, liver cancer, malignant phyllodes tumor of the breast, uveal melanoma, leiomyosarcoma, pancreatic cancer, other tumors, and angiogenesis.
IC50 & Target

CD146

 

MMP-9

 

Caspase 3

 

体外研究
(In Vitro)

Anti-CD146 Antibody (AA98) (10 μg/mL; 30 min radiation, 2-week post-irradiation incubation) 可显著降低受辐照的 SiHa 人宫颈鳞状细胞癌细胞的存活分数,提高其放射敏感性。
Anti-CD146 Antibody (AA98) (10 μg/mL; 30 min radiation, 72 h, 7 days post-irradiation) 可显著增强照射后 72 h 和 7 天时 SiHa 人宫颈鳞癌细胞的辐射诱导凋亡,上调细胞中 Caspase 3 的表达,并下调 Bcl-XL 蛋白的表达。
Anti-CD146 Antibody (AA98) (10-50 μg/mL; 30-90 min) 可抑制 SMMC 7721-CM 诱导的原代人脐静脉内皮细胞中 NF-κB p65 和 p50 的核转位,抑制细胞中 NF-κB 的激活,抑制细胞中 p38 MAPK 的磷酸化。
Anti-CD146 Antibody (AA98) (50 μg/mL; 24 h) 可抑制人原代脐静脉内皮细胞中经 SMMC 7721-CM 增强的 MMP-9 活性和 mRNA 的表达,抑制细胞中 ICAM-1 mRNA 及蛋白表达,抑制细胞迁移。
Anti-CD146 Antibody (AA98) (50 μg/mL; 1 h) 可通过免疫荧光染色观察到,能特异性结合于人脐静脉内皮细胞 (HUVEC) 表面表达的 CD146。
Anti-CD146 antibody (AA98) (150 μg/mL; 16-96 h) 可抑制 SYSH-MPT-02 恶性乳腺叶状肿瘤细胞的增殖、集落形成、迁移、侵袭及胶原收缩,并通过降低磷酸化 AKT 水平抑制 PI3K-AKT 信号通路的激活。
Anti-CD146 antibody (AA98) (150 μg/mL; 35 days) 可抑制原发性恶性乳腺叶状肿瘤类器官的生长。
Anti-CD146 antibody (AA98) 可直接阻断 CD146 与 DCBLD2 蛋白之间的相互作用。
Anti-CD146 Antibody (AA98) (100 μg/mL; 6 h) 可抑制 M17-CM 诱导的原代人视网膜微血管内皮细胞管形成,经 M17-CM 处理后相对总管长减少 33.7%,经 SP6.5-CM 处理后减少 36.4%。
Anti-CD146 Antibody (AA98) (50 μg/mL; 24 h) 可抑制 M17-CM 诱导的原代人视网膜微血管内皮细胞迁移,经 M17-CM 处理后迁移细胞数减少约 62.6%,经 SP6.5-CM 处理后减少约 68.0%。
Anti-CD146 Antibody (AA98) (50 μg/mL; 24 h) 可在原代人视网膜微血管内皮细胞中抑制 VEGF 诱导的 VEGFR-2、AKT 及 p38 信号通路的激活,抑制细胞中 NF-κB p65 的核转位。
Anti-CD146 Antibody (AA98) (50 μg/mL; 20 h) 可抑制 M17 和 SP6.5 葡萄膜黑色素瘤细胞中的血管生成拟态,使 M17 细胞的相对总管长减少 30.2%,SP6.5 细胞的相对总管长减少 42.6%。
Anti-CD146 Antibody (AA98) (50 μg/mL) 可抑制 M17 和 SP6.5 葡萄膜黑色素瘤细胞中 FAK/VE-cadherin 信号通路的激活。
Anti-CD146 Antibody (AA98) (50 μg/mL) 可抑制 M17 和 SP6.5 葡萄膜黑色素瘤细胞中的上皮-间质转化过程,上调 E-cadherin 的表达,同时下调 N-cadherin、波形蛋白 (vimentin) 以及蜗牛转录因子 (snail) 的表达。
Anti-CD146 Antibody (AA98) (40 μg/mL; 24 h) 可抑制 M17 和 SP6.5 葡萄膜黑色素瘤细胞的迁移和侵袭。
Anti-CD146 Antibody (AA98) (1-100 μg/mL; 48 h) 可剂量依赖性地抑制 HUVECs 的增殖,在 100 μg/mL 浓度下抑制率最高可达 62.4%,但对人黑色素瘤 A375 细胞的增殖无抑制作用。
Anti-CD146 Antibody (AA98) (10 μg/mL; 4 h) 可使 HUVECs 向 VEGF/bFGF 的迁移能力降低 75%。

Apoptosis Analysis

Cell Line: human cervical squamous cell carcinoma SiHa cells
Concentration: 10 μg/mL (pre-treatment prior to radiation)
Incubation Time: 30 min (radiation); 72 h, 7 days post-irradiation
Result: Increased the percentage of apoptotic cells in irradiated SiHa cells compared to untreated control cells.

Western Blot Analysis

Cell Line: human cervical squamous cell carcinoma SiHa cells
Concentration: 10 μg/mL (pre-treatment prior to radiation)
Incubation Time: 30 min (radiation)
Result: Up-regulated pro-apoptotic Caspase 3 protein expression in irradiated SiHa cells compared to untreated control cells.
Down-regulated anti-apoptotic Bcl-XL protein expression in irradiated SiHa cells compared to untreated control cells.

Immunofluorescence

Cell Line: human umbilical vein endothelial cells (HUVEC)
Concentration: 50 μg/mL
Incubation Time: 1 h (each antibody step)
Result: Intensively bound to CD146-positive HUVEC, resulting in strong fluorescent staining of the cell surface, similar to the engineered AA98 V_H/L fragment.

Cell Proliferation Assay

Cell Line: SYSH-MPT-02 malignant breast phyllodes tumor cells
Concentration: 150 μg/mL
Incubation Time: 96 h
Result: Significantly suppressed cell proliferation, as measured by reduced absorbance at 492 nm in the MTS assay compared to control groups.
Inhibited colony formation, migration, invasion, and collagen contraction of cells.
Downregulated the level of phosphorylated AKT (p-AKT), while total AKT levels remained unchanged.

Cell Migration Assay

Cell Line: primary human retinal microvascular endothelial cells (HRMEC)
Concentration: 50 μg/mL
Incubation Time: 24 h
Result: Reduced migrated cell counts from 213.7 cells/vision field (IgG control) to 80.0 cells/vision field with M17-CM.
Reduced migrated cell counts from 166.7 cells/vision field (IgG control) to 53.3 cells/vision field with SP6.5-CM.

Western Blot Analysis

Cell Line: primary human retinal microvascular endothelial cells (HRMEC)
Concentration: 50 μg/mL
Incubation Time: 24 h
Result: Significantly reduced VEGF-induced phosphorylation of VEGFR-2 compared to IgG control.
Significantly reduced VEGF-induced phosphorylation of AKT compared to IgG control.
Significantly reduced VEGF-induced phosphorylation of p38 compared to IgG control.

Cell Invasion Assay

Cell Line: uveal melanoma cell lines M17 and SP6.5
Concentration: 40 μg/mL
Incubation Time: 24 h
Result: Significantly reduced invaded cell counts in M17 compared to IgG control.
Significantly reduced invaded cell counts in SP6.5 compared to IgG control.

Cell Proliferation Assay

Cell Line: human umbilical vein endothelial cells (HUVECs), human melanoma A375 cells
Concentration: 1 μg/mL, 10 μg/mL, 100 μg/mL
Incubation Time: 48 h
Result: Inhibited [3H]-thymidine incorporation into HUVEC DNA in a dose-dependent manner: 28.5% inhibition at 1 μg/mL, 43.2% inhibition at 10 μg/mL, and 62.4% inhibition at 100 μg/mL.
Showed only 5%-7% inhibition of HUVEC proliferation with isotype-matched control antibody.
Exhibited no significant inhibitory effect on A375 melanoma cell proliferation across tested concentrations.
体内研究
(In Vivo)

Anti-CD146 Antibody (AA98) (1-15 μg;局部给药;单剂量) 可抑制鸡 CAM 模型中的血管生成。
Anti-CD146 Antibody (AA98) (0.25 mg/只小鼠;腹腔注射;每周 2 次;持续 24 天) 可显著抑制 NOD/SCID 小鼠中恶性乳腺叶状瘤异种移植物的生长,同时伴随 PI3K/AKT 通路激活水平降低、肿瘤细胞增殖受抑及血管生成减少。
Anti-CD146 Antibody (AA98) (4 μg;视网膜下注射;单次给药) 可使视网膜下接种 M17 细胞异种移植物的 BALB/C 裸小鼠的葡萄膜黑色素瘤肿瘤生长降低 71.2%,血管生成抑制 54.7%,并抑制血管拟态 40.6%。
Anti-CD146 Antibody (AA98) (4 μg;视网膜下注射;单次给药) 可使视网膜下接种 SP6.5 细胞异种移植物的 BALB/C 裸鼠的葡萄膜黑色素瘤肿瘤生长抑制 78.4%,血管生成抑制 55.0%,血管拟态抑制 64.9%。
Anti-CD146 Antibody (AA98) (10 mg/kg;腹腔注射;每周 2 次;共 28 天) 可使 BALB/c 裸鼠中人肝癌异种移植物的生长抑制 72%,并能阻止转移。
Anti-CD146 Antibody (AA98) (10 mg/kg;腹腔注射;每周 2 次;持续 24 天) 可使 BALB/c 裸鼠体内人平滑肌肉瘤异种移植物的生长抑制 50%,同时能阻止转移并改变肿瘤血管结构。
Anti-CD146 Antibody (AA98) (10 mg/kg;腹腔注射;每周 2 次;共 18 天) 可使 BALB/c 裸鼠体内人胰腺癌异种移植物的生长抑制 41%,并使肿瘤微血管密度降低约 70%。
131I-labeled Anti-CD146 Antibody (AA98) (97 μg;腹腔注射;单次给药;18 天) 可使 BALB/c 裸鼠体内人胰腺癌异种移植物的生长抑制 75%,并降低肿瘤微血管密度。

Animal Model: white Leghorn (6-day-old embryos from fertilized eggs)
Dosage: 1 μg, 5 μg, 15 μg
Administration: topical; single dose
Result: Induced avascular zones around the antibody-applied areas, where blood vessels became slim and pale.
Animal Model: NOD/SCID (6-week-old female)
Dosage: 0.25 mg/mice
Administration: i.p.; twice a week; 24 days
Result: Inhibited growth of malignant phyllodes tumor patient-derived xenografts, with significantly smaller tumor volumes compared to control groups over the 24-day treatment period.
Decreased levels of phospho-AKT in treated tumor tissues.
Reduced Ki67 staining index in treated tumor tissues.
Lowered density of CD31+ vascular endothelium in treated tumor tissues.
Animal Model: BALB/C nude (4-6 weeks old)
Dosage: 4 μg
Administration: subretinal; single administration
Result: Reduced tumor size by 71.2% compared to the IgG control group.
Reduced microvessel density by 54.7% relative to the IgG control group.
Suppressed vasculogenic mimicry formation by 40.6% relative to the IgG control group.\nReduced tumor size by 78.4% compared to the IgG control group.
Reduced microvessel density by 55.0% relative to the IgG control group.
Suppressed vasculogenic mimicry formation by 64.9% relative to the IgG control group.
Animal Model: BALB/c nude mice (female, 6-week-old, ~20 g, subcutaneous xenograft model with SSMC 7721 cells)
Dosage: 10 mg/kg
Administration: i.p.; twice per week; 28 days
Result: Reduced tumor volume significantly compared with PBS controls, with 72% inhibition of tumor growth after 28 days of treatment.
Prevented metastasis, with no metastases detected via histopathologic analysis, whereas 60%-80% of control mice developed lung and lymph node metastases.
Caused no toxic effects, and no deaths occurred in the treated group, whereas 20% of control mice died between days 14-16.
Animal Model: BALB/c nude mice (female, 6-week-old, ~20 g, subcutaneous xenograft model with SK-LMS-1 cells)
Dosage: 10 mg/kg
Administration: i.p.; twice per week; 24 days
Result: Reduced tumor volume significantly compared with mIgG and PBS controls, with 50% inhibition of tumor growth after 24 days of treatment.
Prevented metastasis, with no metastases detected via histopathologic analysis, whereas 60%-80% of control mice developed lung and lymph node metastases.
Caused no toxic effects, and no deaths occurred in the treated group, whereas 20% of control mice died between days 14-16.
Induced blood vessels with narrowed lumina surrounded by extracellular matrix material, some occluded by thrombi, via histologic analysis of treated tumors.
Animal Model: BALB/c nude mice (female, 6-week-old, ~20 g, subcutaneous xenograft model with SW1990 cells)
Dosage: 10 mg/kg
Administration: i.p.; twice per week; 18 days
Result: Reduced tumor volume significantly compared with mIgG and PBS controls, with 41% inhibition of tumor growth after 18 days of treatment.
Reduced microvessel density in treated tumors by approximately 70% compared with mIgG-treated tumors.
Prevented metastasis, with no metastases detected via histopathologic analysis, whereas 60%-80% of control mice developed lung and lymph node metastases.
Caused no toxic effects, and no deaths occurred in the treated group, whereas 20% of control mice died between days 14-16.
Animal Model: BALB/c nude mice (female, 6-week-old, ~20 g, subcutaneous xenograft model with SW1990 cells)
Dosage: 97 μg (with 18.5 MBq [131I] activity)
Administration: i.p.; single dose; 18 days
Result: Reduced tumor volume significantly compared with [131I]-mIgG controls, with 75% inhibition of tumor growth after 18 days of treatment.
Reduced microvessel density in treated tumors compared with [131I]-mIgG-treated tumors.

化学信息

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础